2022 the Japanese Society of Medical Oncology Annual Meeting (JSMO2022)2022 the Japanese Society of Medical Oncology Annual Meeting (JSMO2022)

JapaneseJP

Call for Abstracts

If you are Japanese, please declare your COI and
submit your abstract to the Japanese website.

Abstract Submission Period

Noon, Tuesday, June 15, 2021 - Noon, Thursday, September 30, 2021 (JST)
  Noon, Monday, October 11, 2021 (JST)

Abstract Submission has been closed.
Thank you for your submission.

Call for Abstracts

General Abstract (Oral / Poster Presentation)

JSMO2022 accepts abstracts for General Abstract.
The Oral and Poster presentations will be given and held on-site and delivered on-demand.

Please select the abstract category from the list below. (The 1st & 2nd choices are required.)

Category Sub-Category Presentation Style
01.
Gastrointestinal Cancer
01-01
Esophageal Cancer
01-02
Gastric Cancer
01-03
Small Bowel Cancer
01-04
Colorectal Cancer
01-05
Other (Appendix Cancer, Anal Cancer, etc.)
Oral / Poster
02.
Hepatobiliary / Pancreatic Cancer
02-01
Liver Cancer
02-02
Gallbladder and Biliary Tract Cancer
02-03
Pancreatic Cancer
Oral / Poster
03.
Lung Cancer / Thoracic Cancer
03-01
Early Stage Non-Small Cell Lung Cancer / Perioperative Treatment
03-02
Locally Advanced Non-Small Cell Lung Cancer
03-03
Metastatic Non-Small Cell Lung Cancer / Chemotherapy
03-04
Metastatic Non-Small Cell Lung Cancer / Tyrosine Kinase Inhibitor
03-05
Metastatic Non-Small Cell Lung Cancer / Immunotherapy
03-06
Small Cell Lung Cancer
03-07
Other (Mesothelioma, Thymic Malignancies, etc.)
Oral / Poster
04.
Hematologic Malignancies
04-01
Lymphoma
04-02
Leukemia
04-03
Other (Myeloma etc.)
Oral / Poster
05.
Breast Cancer
05-01
Early Breast Cancer / Perioperative Therapy
05-02
Metastatic Breast Cancer
Oral / Poster
06.
Gynecologic Cancer
06-01
Gynecologic Cancer
Oral / Poster
07.
Genitourinary Cancer
07-01
Genitourinary Cancer
Oral / Poster
08.
Head and Neck Cancer
08-01
Head and Neck Cancer
Oral / Poster
09.
Rare Cancer / Cancer of Unknown Primary
09-01
Pediatric Oncology
09-02
Central Nervous System Tumors
09-03
Endocrine Cancer, Thyroid Cancer, Neuroendocrine Tumor
09-04
Skin Cancer
09-05
Sarcoma
09-06
Germ Cell Tumor
09-07
Cancer of Unknown Primary
09-08
Other
Oral / Poster
10.
Translational Research / Clinical Pharmacology
10-01
Basic Research
10-02
Clinical Pharmacology
10-03
Innovative Drug Research & Development
10-04
Molecular Diagnostics / Genomic Medicine
10-05
Translational Research
10-06
Companion Diagnostics
10-07
Developmental Therapeutics
10-08
Other
Oral / Poster
11.
Palliative Care / Symptom Management
11-01
Palliative Medicine
11-02
Symptom Management
11-03
Oral Care for Cancer Patients
11-04
Psycho-Oncology
11-05
Other
Oral / Poster
12.
Cross-sectional Program
12-01
Radiation Oncology
12-02
Diagnostic Imaging
12-03
Familial and Hereditary Cancer
12-04
Epidemiology
12-05
Cancer Prevention
12-06
Immunobiology and Immunotherapy
12-07
Drug Therapy
12-08
Other
Oral / Poster
13.
Multidisciplinary Team Program
13-01
Interdisciplinary Approach to Cancer Care
13-02
Rehabilitation
13-03
Outpatient Chemotherapy
13-04
Professional Oncology Education
13-05
Oncology Nursing
13-06
Other
Oral / Poster
14.
Clinical Trial Facilitation Program
14-01
Biostatistics
14-02
Clinical Trial Support
14-03
Trials in Progress
14-04
Research Ethics
14-05
Health Policy / Regulatory Affairs / Reimbursement
14-06
Health Technology Assessment / Health Economics
14-07
Other
Oral / Poster
15.
Patient Advocacy / Survivorship
15-01
Patient Advocacy
15-02
Survivorship
15-03
Geriatric Oncology
15-04
Community Cancer Care
15-05
Adolescents and Young Adults with Cancer
15-06
Other
Oral / Poster
16.
Medical Case Report
16-01
Rare Cancer
16-02
Lung
16-03
Gastrointestinal Tract
16-04
Hematologic Malignancies
16-05
Breast
16-06
Solid Cancers
Poster
17.
COVID-19 and cancer
17-01
COVID-19 and cancer
Oral / Poster
18.
Miscellaneous
18-01
Miscellaneous
Oral / Poster
(a) Abstracts submitted under the “Trials in Progress” category will be posted on the program application and handed out to the participants at the venue on the day of the session.
(Please kindly note that the abstract will be posted on the program application, the information has been changed.)
* Abstract Young Investigator Award
  • Age limitation: The first author must be under the age 40 (as of February 19, 2022)
  • Once you are nominated as a candidate, you will be requested to submit an electronic data for review in December 2021.
  • If you would like to be reviewed as a candidate, please check the box to be reviewed as the candidate for the Abstract Young Investigator Award.
* All submitted abstracts will be reviewed by the Peer Review Committee and decided comprehensively based on the study contents, ethical aspects, and etc. You may choose the presentation style (oral or poster) when you submit an abstract. However, please understand that the congress president will make a final decision on the presentation style, presentation session, as well as acceptance/rejection.

Late-breaking Abstracts

JSMO2022 would like to deepen discussions based on the latest research results. We accept such abstracts as "Late-breaking abstracts".

If you are applying for Late-breaking abstracts, please select "Yes" for the question, "Are you applying for late-breaking abstracts?" and submit an outline and predicted results of your research as interim registration in the abstract text box.
Please complete the abstract submission with the latest research results by Friday, October 29, 2021. (You will be notified by the Secretariat to complete the abstract submission at the beginning of October.)
Due to the extension of the abstract registration period, you will be notified by the Secretariat to complete the abstract submission in the late November.
In addition, we will inform you regarding the deadline for submitting the final version at the same time.

* The accepted results are not influenced even if the actual research results were different from your prediction.

Presidential Session

JSMO2022 will select the abstracts for "Presidential Sessions" from the submitted abstracts this year instead of usual Plenary Session. The selection flow is as follows.

  • Step 1:
    The program committee members choose the following number of abstracts from each category.
    38 abstracts in total: 6 abstracts from each Gastrointestinal Cancer and Lung Cancer /Thoracic Cancer, and each 2 abstracts from other category.
  • Step 2:
    Congress president selects 12 abstracts out of 38 abstracts, and the final selection will be made at the program committee.
    There is one session a day, and each session is 120 minutes consisting of 4 presentations.
    Each presentation is 30 minutes in total (presentation 15 min, Q&A 5 min and discussion 10 min).

Highlight of the Day

Of all the presentations on each day, those with the greatest impact will be selected for review the day after the presentation.

Travel Award

Abstracts submitted by young researchers from outside Japan will be reviewed by the JSMO2022 committee members. Those selected presenters will be awarded partial travel grant for their outstanding works. Abstracts authors are encouraged to apply for Travel Award as outlined below:

Award Details

  • JPY 50,000-100,000 of travel support to investigators from Asia (depending on the quality of abstract).
  • JPY 150,000 of travel support to investigators from others.
  • Congress registration to JSMO2022 is waived
  • Hotel accommodation while you stay in Japan (Single room for four nights).
Note: To qualify for the travel award, you must be free of any commercial grants or support.

Application Acceptance Period

Noon, Tuesday, June 15, 2021 - Noon, Thursday, September 30, 2021, Japan Standard Time (same as the application period for JSMO2022 abstracts)

Eligible Applicants

  • Applicants must be young overseas doctors/researchers, who live outside of Japan, age 45 years old or younger, as of February 19, 2022 (the last day of JSMO2022).
  • Applicants receiving commercial grant support or financial assistance are ineligible.

How to Apply

Please apply by submitting your abstract from the Submission Page (click the "Submit" button).

Award Notification

Recipients will be notified by e-mail at the end of November, 2021.

Publication in "Annals of Oncology"

Abstracts (oral/ poster) submitted in English for JSMO2022 will be published in ESMO/JSMO Scientific Journal, supplement to "Annals of Oncology" (Elsevier).
If you wish to have your abstract published in "Annals of Oncology," please select "Yes".

However, in case that there is any possibility of duplicate publication or encore publication, please refrain from selecting "Yes".

* Terms to be published in Journal "Annals of Oncology" as to poster presentation:

Oral presentations are free of charge but poster presentations are required 5,000JPY of the posting fee of "Annals of Oncology" in addition to the Congress registration fee.

You can cancel publication of the journal after the acceptance notice.
We will contact you to confirm your final intention when the presentation style is decided.

Disclosure of Conflict of Interest at 2022 the Japanese Society of Medical Oncology Annual Meeting

The presenter (the first author) and the principal investigator must disclose the name of any company or for-profit organization related to medicine they have a relationship with, defined as follows: in the following items (3) to (9), (11), (12), exceeding separately stipulated criteria, and (1), (2), (10), (13) if met. The subject period is from January 1, 2018 - December 31, 2020.

COI Disclosure Information

COI Policy (in revision)
Detailed Enforcement Regulations of COI (in revision)

For oral presentation, please use the slide below as a template to disclose conflict of interest.
For poster presentation, please prepare and print out the slide, and put it at lower right of the poster panel.

Template of slide

1 If your study for this presentation is supported by research funds
2 If you are or have been an employee of a company and / or a profit-making organization related to medicine
3 If you have earned > ¥1,000,000 / year as an officer or advisor of a company and/or a profit-making organization related to medicine
4 If you hold > 5% of the stock of a company and/or a profit-making organization related to medicine, or receive dividends > ¥1,000,000/year
5 If you have earned > ¥1,000,000/year as a patent fee from a company and / or a profit-making organization related to medicine
6 If you have earned > ¥500,000/year as a lecture fee from a company and / or a profit-making organization related to medicine
7 If you have earned > ¥500,000/year as a manuscript fee from a company and / or a profit-making organization related to medicine
8 If you have research expenses > ¥1,000,000/year from a company and / or a profit-making organization related to medicine
9 If you have received > ¥1,000,000/year as a certain contribution from a company and / or a profit-making organization related to medicine
10 If you are or have been involved in a certain endowed chair funded by a company and / or a profit-making organization related to medicine
11 If you have > ¥1,000,000/year as a fee for expert comment, judgment or testimony in legal proceedings, or others from a company and / or a profit-making organization related to medicine
12 If you have received remuneration (travel, gifts, or other in-kind payments not directly related to research)equivalent to > ¥50,000/year from a company and / or a profit-making organization related to medicine
13 If you are a representative of an organization for clinical study which receives research expenses(donation, contract, others)from a company and/or a profit-making organization related to medicine

To view the PDF files, you may need, "Adobe Reader" (Download Adobe Reader)

Inquiries regarding COI disclosure

The Secretariat of the Japanese Society of Medical Oncology
E-mail: support@jsmo.or.jp

Ethical Principles for Declaring Ethical Matters of your Abstract

In order to review whether your abstract is conformed to the standard of applicable research ethics such as "GCP", "GPSP", "Ethical guidelines on medical research on humans", "Ethical guidelines on research on human genome and gene analysis", etc., JSMO asks you to declare the following items:

The content of your declaration will not affect the acceptance or rejection of your abstract. Please submit to the following:

  • Does your study include medical research on human subjects, human material or human data? *Required
  • Does your study comply with the Declaration of Helsinki?
  • Was your study approved by an institutional review board before starting the research?

Abstract Submission

If you are Japanese, please declare your COI and
submit your abstract to the Japanese website.

Guideline

We accept abstracts submitted online only through the submission system.
You may enter the submission page from the "Abstract Submission" button at the bottom of this page.

  • Author information and abstracts must be submitted in English.
  • Abstract title must be up to 120 single-byte characters. (including spaces)
  • Abstract text must be up to 2,000 single-byte characters. (including spaces)
  • The maximum of 20 authors (first author & co-authors) can be registered.
  • The maximum of 20 affiliations (including the affiliation of the first author) can be registered.
  • Please structure your abstract as follows:
    Background:
    Methods:
    Results:
    Conclusion:
  • Any chart or diagram cannot be included.
  • Regarding the special characters, please refer ‘How to type special characters’ in the registration page.
  • In the registration page, you will be asked to enter the information such as "Application for Late-breaking abstracts", "Application for Virtual Foreign Contribution Awards (former Travel Awards)", "Publication in Annals of Oncology" as well as COI information.
* It is recommended that you prepare your abstract text by Word / text file in advance, and then copy it on the registration page.
* The abstract registration ID number and your password which will be required to confirm, modify, delete, and add abstracts will be issued and sent to the first author by email when you complete your abstract submission. Please make sure to register the correct email address and keep them by yourself.
The congress secretariat will NOT keep track of your information.

Confirmation / Modification / Deletion of Submitted Abstract & Additional Submission

You can access to confirm/modify/delete/add abstracts during the abstract submission period.
The ID number and password will be required to enter the “Confirmation / Modification / Deletion of Submitted Abstract & Additional Submission” Page.

Acceptance/Rejection Notification

Notification of acceptance/rejection will be sent to the first author by email in the Early December, 2021.

Abstract Submission

Abstract Submission Page

Abstract Submission

Confirmation / Modification / Deletion of Submitted Abstract & Additional Submission Page

Confirmation / Modification / Deletion of Submitted Abstract & Additional Submission Page

Inquiries for Abstract Submission

Congress Secretariat
c/o Convention Linkage, Inc.
2 Sanbancho, Chiyoda-ku, Tokyo, 102-0075 Japan
E-mail: jsmo2022@c-linkage.co.jp

Copyright ©
2022 the Japanese Society of Medical Oncology Annual Meeting.
All Rights Reserved.

PAGE TOP